However, although many inhibitors of IGF receptors (IGFR) have been developed and promising antitumor activity has been shown, clinical studies revealed very limited efficacy of IGFR inhibitors as single-agent in HCC therapy [9,10]. The gene discussed is IGF1R; the disease is hepatocellular carcinoma.